AI Article Synopsis
Article Abstract
Background: Cancer cases have escalated by approximately 12% since 1900 and the incidence rate has increased faster for females than males. The discovery of cisplatin in 1965 paved the way for metal-based compounds as cancer therapeutics. Unfortunately, cisplatin and other platinum-based medicines cause severe side effects. Therefore, non-platinum metal complexes have been developed as alternate cancer drugs. Among non-platinum metal complexes, organotins are the most effective candidates in oncology due to their wide range of anticancer activities with relatively minimal toxicities towards healthy cells, better excretion from the body, and fewer side effects than platinum drugs.
Methods: Using DOI searching, advances made by organotin(IV) complexes coordinated with Sn-O, Sn-N and Sn-S as chemotherapeutic agents since 2018 are summarized in this article. Their chemical structure and in vitro antiproliferative activity in terms of IC/EC/LD are cumulated.
Results: As reflected in this perspective, organotin(IV) complexes are found to induce high cell death via apoptosis, and also several complexes demonstrated anticancer activity even higher than standard drugs.
Conclusion: Undoubtedly, the organotin(IV) complexes could bring hope to morbidity and mortality of human beings caused by fast-spreading cancer worldwide and can play an important role in drug discovery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871520622666220520095549 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Organotin(IV) derivatives of 4-chloro-2-methylphenoxyacetic acid: synthesis, spectral characterization, X-ray structures, anticancer, enzyme inhibition, antileishmanial, antimicrobial and antioxidant activities.
J Biomol Struct Dyn
January 2025
Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan.
Four organotin(IV) carboxylate complexes; (CH)SnL (), CHSnL (), (CH)SnL () and (CH)SnL () are synthesized by the condensation reaction of organotin(IV) chlorides with sodium-4-chloro-2-methylphenoxyacetate (). The FT-IR spectra suggested bridging/chelating bidentate coordination of the ligand to the tin atom. Single-crystal XRD analysis authenticated the FT-IR findings for and .
View Article and Find Full Text PDFAnticancer behavior of cyclometallated iridium(III)-tributyltin(IV) carboxylate schiff base complexes with aggregation-induced emission.
J Inorg Biochem
January 2025
Key Laboratory of Life-Organic Analysis of Shandong Province, Institute of Anticancer Agents Development and Theranostic Application, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China. Electronic address:
Cyclometallated iridium(III) and organotin(IV) carboxylate complexes have shown potential application value in the field of anticancer. However, the widespread aggregation-caused quenching (ACQ) effect of these complexes is not conducive to the exploration of their targeting and anticancer mechanism, and the idea of aggregation-induced emission (AIE) effect can effectively solve this problem. Then, AIE-activated cyclometallated iridium(III)-tributyltin(IV) carboxylate Schiff base complexes were designed and prepared in this study.
View Article and Find Full Text PDFSynthesis, structures, and cytotoxicity insights of organotin(IV) complexes with thiazole-appended pincer ligand.
J Inorg Biochem
January 2025
Department of Chemistry, University of Kentucky, 506 Library Drive, 146 Chemistry-Physics Building, Lexington, KY 40506-0055, USA. Electronic address:
Article Synopsis
- Diorganotin complexes with various compositions were synthesized by reacting organotin oxides with a specific ligand in toluene, and a mono-n-butyltin complex was prepared using acetonitrile.
- These complexes were characterized through techniques like FT-IR, NMR spectroscopy, and X-ray diffraction, revealing their coordinated structures and forms.
- The antitumor activities of the first five complexes were tested on T-47D breast cancer cells, with compound 3 showing the highest effectiveness and potential for selective toxicity, positioning it as a promising candidate for breast cancer treatment.
Organotin(IV) complexes of tridentate (ONO) hydrazone ligands: synthesis, spectral characterization, antituberculosis, antimicrobial, anti-inflammatory, molecular docking and cytotoxicity studies.
Biometals
February 2025
Department of Chemistry, Guru Jambheshwar University of Science & Technology, Hisar, Haryana, 125001, India.
Infectious diseases have a significant impact in the historical trajectory of humanity, exerting profound influence on societies, driving advancements in medical science, and significantly impacting individuals on a worldwide scale. Consequently, this research endeavours to identify potent agents combatting tuberculosis, inflammation, and microbial deformities. The investigation focuses on hydrazones (1,2) endowed eight organotin(IV) complexes, where hydrazones were derived from 2-acetyl-1H-indene-1,3(2H)-dione and 2-phenoxypropanehydrazide/2-(2,4-dichlorophenoxy)propanehydrazide.
View Article and Find Full Text PDFOrganotin(IV) complexes derived from 2,6-diacetylpyridine bis(2-hydroxybenzoylhydrazone) as prospective anti-proliferative agents: Synthesis, characterization, structures and in vitro anticancer activity.
J Inorg Biochem
December 2024
Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal; Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal. Electronic address:
Six organotin(IV) complexes, viz., [MeSn(L)] (1), [n-BuSn(L)] (2), [n-OctSn(L)] (3), [BzSn(L)]·0.5CH (4), [n-BuSn(L)Cl] (5), and [PhSn(L)Cl] (6), were synthesized using a 2,6-diacetylpyridine bis(2-hydroxybenzoylhydrazone), HL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!